BioNTech SE (NASDAQ:BNTX) Short Interest Up 15.6% in August

BioNTech SE (NASDAQ:BNTX) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 2,440,000 shares, a growth of 15.6% from the August 15th total of 2,110,000 shares. Based on an average daily trading volume, of 690,400 shares, the short-interest ratio is presently 3.5 days.

Analyst Ratings Changes

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $180.00 price target on shares of BioNTech in a report on Monday, August 28th. HSBC started coverage on BioNTech in a research note on Friday, July 14th. They issued a “buy” rating and a $124.00 target price for the company. Finally, Morgan Stanley decreased their price target on BioNTech from $119.00 to $116.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 8th. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $158.69.

BioNTech Trading Up 0.7 %

Shares of NASDAQ BNTX traded up $0.80 during midday trading on Tuesday, hitting $109.84. The stock had a trading volume of 156,022 shares, compared to its average volume of 691,840. The company has a quick ratio of 10.32, a current ratio of 10.56 and a debt-to-equity ratio of 0.01. BioNTech has a 1-year low of $95.50 and a 1-year high of $188.99. The company has a market capitalization of $26.47 billion, a price-to-earnings ratio of 6.17 and a beta of 0.17. The company has a fifty day moving average price of $112.07 and a 200 day moving average price of $114.57.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 7th. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.04. BioNTech had a net margin of 47.37% and a return on equity of 21.46%. The firm had revenue of $167.70 million for the quarter, compared to analysts’ expectations of $628.13 million. During the same period in the previous year, the company posted $7.31 earnings per share. BioNTech’s revenue was down 94.8% compared to the same quarter last year. On average, analysts predict that BioNTech will post 6.62 earnings per share for the current year.

Institutional Trading of BioNTech

A number of institutional investors have recently added to or reduced their stakes in the business. Robeco Institutional Asset Management B.V. lifted its stake in shares of BioNTech by 178.8% during the first quarter. Robeco Institutional Asset Management B.V. now owns 74,733 shares of the company’s stock worth $9,309,000 after purchasing an additional 47,924 shares in the last quarter. B. Metzler seel. Sohn & Co. AG boosted its holdings in BioNTech by 1.4% in the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock worth $1,366,000 after acquiring an additional 150 shares during the period. Endurant Capital Management LP purchased a new position in BioNTech in the 4th quarter worth approximately $3,254,000. Sector Gamma AS grew its position in BioNTech by 11.9% in the first quarter. Sector Gamma AS now owns 26,554 shares of the company’s stock valued at $3,308,000 after acquiring an additional 2,816 shares in the last quarter. Finally, Flossbach Von Storch AG raised its stake in shares of BioNTech by 4.6% during the first quarter. Flossbach Von Storch AG now owns 3,432,334 shares of the company’s stock valued at $427,566,000 after purchasing an additional 149,611 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.